A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security . Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm. | May 22, 2022 . Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases . | April 5, 2022 Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Use the PitchBook Platform to explore the full profile. Atara is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4). She serves as Chairman of AnaptysBio and as a Director at Millendo Therapeutics. This net worth evaluation does not reflect any other assets that Mr. Koppikar may own. Delighted to announce the planned acquisition of the Atara T-Cell Operations and Manufacturing facility in . Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara's cell therapy manufacturing facility in . Senior Manager Talent Acquisition. Alex Yoo. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and . Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara's cell therapy manufacturing facility . | April 5, 2022 Atara Biotherapeutics Inc (NASDAQ:ATRA) was in 22 hedge funds' portfolios at the end of the second quarter of 2020. April 4, 2022 - 4:01 pm. Carol G Gallagher, Pharm.D. 3 Min Read. FUJIFILM (FUJIY) is acquiring a cell therapy manufacturing facility from Atara Biotherapeutics (ATRA) for $100M.The Thousand Oaks, Calif.-based facility has the flexibility to produce. Biopharmaceutical executive Charlene Banard has joined Atara Biotherapeutics Inc. as chief technical officer. (Employees figure is modelled). FUJIFILM (FUJIY) is acquiring a cell therapy manufacturing facility from Atara Biotherapeutics (ATRA) for $100M.The Thousand Oaks, Calif.-based facility has the flexibility to produce. TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Atara Bio's programs include molecularly targeted product candidates and T-cell product candidates. 1. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop . TOKYO, April 5, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial . Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. 311. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for . SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Alex is based out of Los Angeles County, California, United States and works in the Biotechnology industry. Atara Biotherapeutics celebrated AAPI Heritage Month by getting to know a few of our Atarians' heritage, culture and their favorite recipes to Asian cuisine and drinks! View Alex Yoo's email address (a*****@atarab***.com) and phone number. Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Over the last five trading days since the potential acquisition was announced, bluebird is up 17.5%, ZIOPHARM Oncology is up 15%, and Atara Biotherapeutics is up 11% relative to the IBB which is . Date 1/26/2022 5:00:51 PM "We are thrilled that through this acquisition we will add approximately 140 talented staff from Atara's cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. "Bringing a seasoned leader like Charlene to Atara further . TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell . Director. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary . TOKYO, April 4, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease . (-2.29%) -$0.22. Facilitate sending and receiving precious biological samples. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative . AMS means the Federal Aviation Administration's Acquisition Management System. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . ATRA: Atara Biotherapeutics . TOKYO, FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. IMS shall have the meaning set forth in the recitals hereto. Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE . Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with . SOUTH SAN FRANCISCO, Calif. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the . Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. $9.40. 1w. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative . Atara Biotherapeutics. FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. 650-278-8930. www.atarabio.com. We are considered a leading off-the-shelf T-cell immunotherapy . Advisor Insights; Personal Finance; Market Volatility; Retirement Planning; Start Investing; Save for College; Best Investments; See All The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. The stock options have a ten-year term and an exercise price of $4.83 per share, equal to the per share closing price of Atara's common stock as reported by Nasdaq on June 1, 2022. The Atara Biotherapeutics Management Team. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Dan Maziasz Head of Corporate Strategy and Business Development The estimated net worth of Jakob Dupont is at least $841,110.96 as of May 17th, 2022. Los Angeles Metropolitan Area. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic . Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Here's why. Current Price. Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. "We are thrilled that through this acquisition we will add approximately 140 talented staff from Atara's cell therapy manufacturing facility to the . Today's Change. This means the bullish number of . The all time high for this statistics is 17. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative . . Atara Biotherapeutics, Inc. has 4 employees at this location. Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022. This net worth estimate does not reflect any other assets that Dr. Dupont may own. TOKYO, April 5, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Atara Biotherapeutics is a leader in CAR T-cell immunotherapy and develop therapies for patients with cancer and autoimmune diseases. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases . More about Atara Bio. Company profile. Apr 04, 2022 4:01pm EDT. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . Molecularly targeted product candidates include PINTA 745, STM 434 and ATA 842, members of the TGF-beta . Atara Biotherapeutics, Inc. (), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 115,059 restricted stock units of Atara s common stock to 13 newly hired employees and stock options to purchase an aggregate of 118,745 shares of . Atara Biotherapeutics, Inc. operates as a clinical stage biopharmaceutical company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Atara Biotherapeutics, Inc. ( @Atarabio) is a pioneer in T-cell . The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies . 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA 94080. On April 4, 2022 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara's cell therapy manufacturing . Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million . Dr. Dupont owns 163,006 shares of Atara Biotherapeutics stock worth more than $841,111 as of May 19th. Sep 2019 - Mar 20222 years 7 months. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. FUJIFILM Corporation today announced that it has completed the acquisition of a. (Fujifilm), has completed the acquisition . Manher (AJ) Joshi was appointed to the role of Atara Biotherapeutics' Chief Medical Officer in September 2018. Arena means an enclosed building: Pharmaceutical care means the provision of drug therapy and. Responsible for acquisition and coordinating installation of new lab assets. From 2008-2011, Carol was the president . Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transform . Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. FUJIFILM Corporation today announced that it has completed the acquisition of a. Alex works at Atara Biotherapeutics as Sr. Director, Talent Acquisition. Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of LongTerm Strategic Partnership with . Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune. Thanks for . $875M. There are 8 companies in the Atara Biotherapeutics, Inc. corporate family. TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for USD 100 million.The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth . About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for . Company Description: Atara Biotherapeutics, Inc. is located in Thousand Oaks, CA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. With our lead program in Phase 3 clinical development, Atara is the most . Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. . We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. In connection with the Quarterly Report of Atara Biotherapeutics, Inc. . Atara Biotherapeutics has reached an . Banard will oversee process science and development, quality, manufacturing and supply. Information on acquisition, funding, investors, and executives for Atara Biotherapeutics (T-Cell Operations and Manufacturing Facility in Thousand Oaks, California). 3 months ago - Business . Mr. Koppikar owns 161,369 shares of Atara Biotherapeutics stock worth more than $806,845 as of May 12th. SVP and Head of Business Development and Corporate Strategy at Atara Biotherapeutics . Item 2.01 Completion of Acquisition or Disposal of Assets. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc., (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Market Cap. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop . Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. SOUTH SAN FRANCISCO, Calif., May 05, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catalysts. Director. FRANKFURT (Reuters) - Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group firms up its commitment . 04/04/22 4:01 PM Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm 03/23/22 7:30 AM Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer Buyouts in the . Dr. Carol Gallagher serves as the Lead Independent Director of Atara Biotherapeutics. About Atara. He brings more than 15 years of clinical, drug development, and commercialization experience in orphan and large markets to his role . This partnership and acquisition was first announced in January 2022. . TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million.The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies' global network . About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.With our lead program in Phase 3 clinical development and currently under review to support registration in . The estimated net worth of Utpal Koppikar is at least $806,845.00 as of August 17th, 2021. As stated earlier, on January 26, 2022, Atara Biotherapeutics, Inc. a Delaware company (the "Company"), has entered into an asset purchase agreement (the "Asset Purchase Agreement" and the transactions contemplated therein, the "Transaction") by and between the Company, FUJIFILM Diosynth Biotechnologies California, Inc . He joined Atara in August 2016, initially serving as Senior Vice President, Global Medical Affairs. Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. She recently joined the life sciences practice of New Enterprise Associates as a Partner. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de.